These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26783359)

  • 1. Cost and Consequences of Nonadherence With Oral Bisphosphonate Therapy: Findings From a Real-World Data Analysis.
    Sharman Moser S; Yu J; Goldshtein I; Ish-Shalom S; Rouach V; Shalev V; Modi A; Chodick G
    Ann Pharmacother; 2016 Apr; 50(4):262-9. PubMed ID: 26783359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
    Modi A; Tang J; Sen S; Díez-Pérez A
    Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and consequences of noncompliance to oral bisphosphonate treatment.
    Eisenberg DF; Placzek H; Gu T; Krishna A; Tulsi BB
    J Manag Care Spec Pharm; 2015 Jan; 21(1):56-65. PubMed ID: 25562773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
    Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
    J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
    Modi A; Siris ES; Tang J; Sen S
    Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates.
    Imel EA; Eckert G; Modi A; Li Z; Martin J; de Papp A; Allen K; Johnston CC; Hui SL; Liu Z
    Bone; 2016 Feb; 83():267-275. PubMed ID: 26657827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
    Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
    Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men.
    Mikyas Y; Agodoa I; Yurgin N
    Appl Health Econ Health Policy; 2014 Jun; 12(3):267-77. PubMed ID: 24477429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
    Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
    BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users.
    Curtis JR; Westfall AO; Cheng H; Lyles K; Saag KG; Delzell E
    J Bone Miner Res; 2008 Sep; 23(9):1435-41. PubMed ID: 18442318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries.
    Kjellberg J; Jorgensen AD; Vestergaard P; Ibsen R; Gerstoft F; Modi A
    Osteoporos Int; 2016 Dec; 27(12):3535-3541. PubMed ID: 27394414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis.
    Richards JS; Cannon GW; Hayden CL; Amdur RL; Lazaro D; Mikuls TR; Reimold AM; Caplan L; Johnson DS; Schwab P; Cherascu BN; Kerr GS
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1864-70. PubMed ID: 22740421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008.
    Siris ES; Pasquale MK; Wang Y; Watts NB
    J Bone Miner Res; 2011 Jan; 26(1):3-11. PubMed ID: 20662073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
    Cotté FE; Mercier F; De Pouvourville G
    Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment.
    Penton H; Hiligsmann M; Harrison M; Reginster JY; Boonen A; Bansback N
    Osteoporos Int; 2016 Sep; 27(9):2697-2707. PubMed ID: 27155885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential clinical and economic impact of nonadherence with osteoporosis medications.
    Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
    Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.